Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI363 in ES-SCLC Following Progression on Immunotherapy
NCT07289048Phase 2Not yet recruiting
- Start
- Dec 2025
- Primary completion
- Dec 2027
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
01
Overview
A Phase 2 trial of IBI363 in small cell lung cancer (SCLC). Planned start Dec 2025; status: not yet recruiting.
02
Drugs
IBI363
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07289048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07289048.